Momenta Pharmaceuticals and Mylan N.V. announced today that M834, the companies’ proposed biosimilar of Bristol-Myers Squibb’s Orencia (abatacept), did not meet its primary pharmacokinetic (PK) endpoints in a phase 1 study comparing the PK, safety, and immunogenicity of M834 compared with US- and EU-sourced Orencia.
Momenta Pharmaceuticals and Mylan N.V.
today that M834, the companies’ proposed biosimilar of Bristol-Myers Squibb’s Orencia (abatacept), did not meet its primary pharmacokinetic (PK) endpoints in a phase 1 study comparing the PK, safety, and immunogenicity of M834 compared with US- and EU-sourced Orencia.
The phase 1
was a randomized, double-blind, 3-arm, parallel-group, single-dose, subcutaneous administration clinical study in 243 healthy volunteers ages 18 to 55.
Primary outcome measures included:
Secondary outcome measures included:
Orencia is approved in the United States, European Union, and Japan for the treatment of rheumatoid arthritis (RA), including the treatment of those patients who have not been helped enough by other medicines for RA. Orencia may be used in adults alone or with RA treatments other than tumor necrosis factor (TNF) antagonists. In the United States and European Union, Orencia is also approved for the treatment of psoriatic arthritis and juvenile idiopathic arthritis.
In 2016, worldwide
of Orencia totaled $2.4 billion. There are no currently approved abatacept biosimilars; the patents on the originator product expire in the US in October 2019 and in Europe in December 2017.
According to an August 2017 study published in Clinical Therapeutics, the overall cost per patient per year of infusion therapy for Orencia was $46,532.
The Generics and Biosimilars Initiative
that the only other abatacept biosimilar being developed is that of BioXpress Therapeutics.
Craig Wheeler, president and CEO of Momenta Pharmaceuticals, said that the phase 1 results were unexpected and disappointing. “We are in the process of gathering the full data set and will work with Mylan to fully analyze these data to better understand the study results and evaluate next steps for this program,” he said. “We remain committed to executing on our biosimilar portfolio.”
Mylan and Momenta are collaborating on biosimilars, and are jointly responsible for product development, with Mylan leading worldwide commercialization efforts.
Momenta’s biosimilar pipeline includes a number of programs, but only 2 have been publicly disclosed—M834 and a biosimilar of adalimumab (AbbVie’s Humira), M923.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Sintilimab, Bevacizumab Biosimilar, HAIC Improves Survival in Patients With Unresectable HCC
April 14th 2024Positive results of sintilimab, IBI305, and hepatic arterial infusion chemotherapy (HAIC) treatment showed shrinking tumors and previously converting inoperable hepatocellular carcinoma (HCC) to resectable HCC with manageable adverse effects.